Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Colorectal Cancer Clinical Trial

Official title:

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06052852
• Other study ID #: BBI-20233042
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 11, 2023
• Est. completion date: March 2028

Study information

• Verified date: February 2024
• Source: Bolt Biotherapeutics, Inc.
• Contact: Bolt Biotherapeutics
• Phone: +1 650 434 8640
• Email: clinicaltrials[@]boltbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A first-in-human study using BDC-3042 as a single agent and in combination with pembrolizumab in patients with advanced malignancies

Description:

This study has four parts. Part 1 is a dose escalation of BDC-3042 as a single agent to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), or maximum protocol dose (MPD) recommended for Part 3. In Part 3, the selected dose will be administered as monotherapy to patients with selected advanced malignancies. Part 2 is a dose escalation of BDC-3042 in combination with pembrolizumab to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), or maximum protocol dose (MPD) recommended for Part 4. In Part 4, the selected dose will be administered in combination with pembrolizumab to patients with selected advanced malignancies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 167
• Est. completion date: March 2028
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to understand and sign the informed consent form

2. Age 18 years or older at the time of informed consent

3. Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

5. Subjects enrolled in Part 1 and Part 2 dose escalation cohorts must have:

a. Histologically/cytologically confirmed triple-negative breast cancer (TNBC), clear cell renal cell cancer (ccRCC), ovarian cancer, head and neck cancer, colorectal cancer, or non-small cell lung cancer (NSCLC) that is metastatic or unresectable with tumor progression after standard therapy who have no options for standard therapies which are known to confer clinical benefit. Subjects with ovarian cancer must have platinum resistant or platinum-refractory tumors.

6. Subjects enrolled in Part 3 and Part 4 dose expansion cohorts must have histologically/cytologically confirmed metastatic or unresectable TNBC or NSCLC with tumor progression after standard therapy who have no options for standard therapies which are known to confer clinical benefit.

7. Adequate organ function defined as follows:

1. Hematology: i. Absolute neutrophil count = 1500 cells/mm3; ii. Platelet count = 75,000 cells/mm3; iii. Hemoglobin = 9 g/dL (and without transfusion within 7 days)

2. Renal: creatinine clearance = 30 mL/min by Cockcroft-Gault estimate

3. Coagulation: Prothrombin time or international normalized ratio and activated partial thromboplastin time = 1.5 × upper limit of normal (ULN) (unless receiving anticoagulation therapy)

4. Hepatic: i. Aspartate aminotransferase and alanine transaminase (ALT) = 3 × ULN (or = 5 × ULN in subjects with known hepatic metastases); ii. Total bilirubin = 1.5 × ULN (isolated value > 1.5 × ULN is acceptable if direct bilirubin is < 35% of total)

8. Developed tumor progression after treatment with all standard therapies or have no appropriate available therapies

9. Expected life expectancy of > 12 weeks per the Investigator

10. Women of childbearing potential (WOCBP) should use a highly effective contraceptive measure (a method that can achieve a failure rate of less than 1% per year) during treatment and until 4 weeks after the end treatment.

11. Potent men that are partners of WOCBP must be willing to use condoms in combination with a second highly effective method of female contraception and agree not to donate sperm from screen through at least 4 months after last dose of study treatment. A male partner will be considered as potent unless surgically sterilized (with appropriate documentation of sterility).

Exclusion Criteria:

1. Active systemic yeast infection within 4 weeks before study treatment

2. Prior hospitalization for asthma during past year

3. Central nervous system metastases except for disease that is asymptomatic, clinically stable, and has not required steroids for at least 14 days before starting study treatment

4. Cardiac disease including:

1. Congestive heart failure New York Heart Association classes II-IV

2. QTcF prolongation > 450 milliseconds (ms) based on a 12-lead electrocardiogram (ECG) in triplicate or > 480 ms for subjects with bundle branch block

3. Serious or uncontrolled cardiac arrhythmia within 6 months before starting study treatment

4. Myocardial infarction, unstable angina pectoris, or coronary angioplasty, stenting, or surgery within 6 months before starting study treatment

5. Serious or uncontrolled hypertension (= 180 mmHg systolic or = 120 mmHg diastolic) within 6 months before starting study treatment

6. Pericarditis or pericardial effusion that is symptomatic within 6 months before starting study treatment

5. Pulmonary disease including idiopathic pulmonary fibrosis, noninfectious interstitial lung disease, pneumonitis, chronic obstructive pulmonary disease (requiring daily treatment for dyspnea, oxygen therapy on an ongoing basis, or hospitalization within the past 6 months)

6. Hepatic disease resulting in symptomatic ascites, encephalopathy, coagulopathy, esophageal/gastric varices, or persistent jaundice

7. Arterial thrombotic event, stroke, or transient ischemia attack within 6 months before starting study treatment

8. Bleeding diathesis or uncontrolled bleeding within 7 days before starting study treatment

9. Bone marrow transplant or solid organ transplant

10. Infection including:

1. Disease requiring systemic therapy within 7 days before starting study treatment

2. Ongoing COVID-19 as determined by viral testing

3. Active human immunodeficiency virus (HIV) infection as determined at screening

4. Active hepatitis B infection as determined at screening

5. Active hepatitis C infection as determined at screening

11. Autoimmune disease requiring systemic disease-modifying or immunosuppressive therapy within 2 years before starting study treatment. Exceptions include disease managed with only replacement therapies (eg, thyroxine, etc.)

12. History of hemophagocytic lymphohistiocytosis/macrophage activation syndrome

13. Malignancy within 2 years before starting study treatment other than the disease under study. Exceptions include indolent or definitively treated disease not expected to require treatment during the study, affect the safety of subjects, or affect the endpoints of the trial

14. Any medical condition requiring corticosteroids (> 10 mg daily oral prednisone or equivalent) or other systemic immunosuppressive therapy within 28 days before starting study treatment. Exception: Intermittent or sporadic use of inhaled or topical steroids is allowed

15. Residual toxicity from previous treatment including:

1. Toxicity related to prior treatment not resolved to Grade 1

2. Neuropathy Grade > 2 Note: Exceptions to the above criteria include toxicities that do not pose a risk to vital organ systems (eg, alopecia) or toxicities that are stable as managed by replacement therapies (eg, hypothyroidism)

16. Subjects receiving immune checkpoint inhibitor: Toxicity Grade 3 related to prior immunotherapy and leading to treatment discontinuation

17. Any investigational agent within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter

18. Radiation therapy within 14 days before starting study treatment

19. History of severe hypersensitivity to any ingredient of BDC-3042 or study treatment (as applicable for combination study treatment)

20. Received live/attenuated virus vaccine within 28 days before starting study treatment

21. Major surgery within 28 days of starting study treatment (consult with Medical Monitor)

22. Actively enrolled in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study

23. Patient is a lactating mother or pregnant as confirmed by pregnancy tests within 7 days prior to start of study treatment

24. Patient is unwilling or unable to follow protocol requirements

25. Ongoing bowel perforation or presence of bowel fistula or intra-abdominal abscess

26. Any condition that, in the opinion of the Investigator, would interfere with evaluation of BDC-3042 or interpretation of the patient's safety or study results

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Clear Cell Renal Cell Carcinoma
• Colorectal Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• BDC-3042
Dectin-2 agonist antibody
• Pembrolizumab
Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells

Locations

Country	Name	City	State
United States	NEXT Oncology	Austin	Texas
United States	NEXT Virginia	Fairfax	Virginia
United States	MD Anderson Cancer Center	Houston	Texas
United States	NEXT Oncology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Bolt Biotherapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0	Escalation period	2 years
Primary	Incidence and nature of AEs considered by the Investigator or Sponsor to be clinically relevant, attributable to study treatment, and meeting dose-limiting toxicity (DLT) criteria	Escalation period	Up to 21 days
Primary	Objective response rate (ORR) using RECIST 1.1	Expansion period	2 years
Secondary	Objective response rate (ORR) using RECIST 1.1	Escalation period	2 years
Secondary	Duration of response (DOR)	Escalation and expansion periods	2 years
Secondary	Disease control rate (DCR) of confirmed complete response (CR), partial response (PR), or stable disease (SD) lasting 4 or more weeks	Escalation and expansion periods	2 years
Secondary	Progression Free Survival (PFS)	Escalation and expansion periods	2 years
Secondary	Best overall response (CR, PR, SD, progressive disease)	Expansion period	2 years
Secondary	Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0	Expansion period	2 years
Secondary	PK (Cmax) of BDC-3042	Escalation and expansion periods	2 years
Secondary	PK (Cmin) of BDC-3042	Escalation and expansion periods	2 years
Secondary	PK (AUC0-t) of BDC-3042	Escalation and expansion periods	2 years
Secondary	PK (AUC0-inf) of BDC-3042	Escalation and expansion periods	2 years
Secondary	PK (CL) of BDC-3042	Escalation and expansion periods	2 years
Secondary	PK (Vc or Vss) of BDC-3042	Escalation and expansion periods	2 years
Secondary	PK (Terminal t1/2) of BDC-3042	Escalation and expansion periods	2 years
Secondary	Incidence of anti-BDC-3042 antibodies	Escalation and expansion periods	2 years